PCSA Stock Risk & Deep Value Analysis
Processa Pharmaceuticals Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About PCSA Stock
We analyzed Processa Pharmaceuticals Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran PCSA through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
PCSA Risk Analysis & Red Flags
What Could Go Wrong
The company's extremely limited cash runway, likely under $2 million based on previous reports, combined with ongoing cash burn means it will require substantial dilutive financing in the near future. If clinical trial results for NGC-Cap are negative or insufficient to attract partnership/funding, the company could face severe liquidity issues, leading to significant stock price decline or even potential delisting.
Risk Matrix
Overall
Aggressive
Financial
High
Market
Medium
Competitive
High
Execution
High
Regulatory
High
Red Flags
- ⚠
Extremely low cash position ($1.4M in crypto reported previously, no new details provided in research but likely still minimal)
- ⚠
Persistent negative net income and cash flow from operations (typical for pre-revenue biotech, but indicates high funding needs)
- ⚠
Absence of institutional ownership data, implying low institutional interest/validation
- ⚠
Lack of detailed financial data in current research context suggests either low transparency or very minimal analyst coverage
Upcoming Risk Events
- 📅
Negative or inconclusive Phase 2 NGC-Cap interim data
- 📅
Failure to secure additional funding, leading to further significant dilution or pipeline delays
- 📅
Competitor drug advancements impacting market opportunity
When to Reconsider
- 🚪
Negative or inconclusive results from NGC-Cap Phase 2 interim analysis
- 🚪
Announcement of highly dilutive capital raise (>30% share increase without significant clinical progress)
- 🚪
Cash position falling below $1M or explicit 'going concern' warning in next filings
Unlock PCSA Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Processa Pharmaceuticals Inc (PCSA) Do?
Market Cap
$7.05M
Sector
Healthcare
Industry
Biotechnology
Employees
10
Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine, which is in Phase 2 clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers. It also develops non-oncology drugs consisting of PCS12852 that is in Phase 2B clinical trials for treatment of gastroparesis; and PCS499 for the treatment of glomerular disease. The company has license agreements with Elion Oncology, Inc.; Ocuphire Pharma, Inc.; Aposense, Ltd.; Yuhan Corporation; and CoNCERT Pharmaceuticals, Inc. Processa Pharmaceuticals, Inc. was founded in 2017 and is based in Hanover, Maryland.
Visit Processa Pharmaceuticals Inc WebsiteInvestment Thesis
PCSA represents a high-risk, high-reward investment predicated on the successful clinical development of its oncology pipeline, primarily NGC-Cap. With a minuscule market cap and strong insider buying, any positive clinical milestone could trigger a multi-fold increase, targeting unmet needs in oncology. However, the extreme financial fragility and cash burn present significant dilution risks and require careful monitoring.
Is PCSA Stock Undervalued?
Unlock the full AI analysis for PCSA
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
PCSA Price Targets & Strategy
12-Month Target
$5.50
Bull Case
$15.00
Bear Case
$0.50
Valuation Basis
Based on a speculative 0.05x projected peak sales revenue of $100-300M for NGC-Cap, reflecting early-stage clinical risk and high discount rate.
Entry Strategy
High-risk entry; consider dollar-cost averaging near strong support levels if any material positive clinical data emerges. Current price ($2.7) is below recent insider buy price ($2.97), offering a slight discount.
Exit Strategy
Take profit on significant positive clinical milestones (e.g., successful Phase 2 data, initiation of Phase 3, partnership announcements). Stop-loss below recent lows ($1.50) if no positive catalysts emerge or cash concerns escalate.
Portfolio Allocation
0.5-1% for aggressive risk tolerance only.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is PCSA Financially Healthy?
Valuation
P/E Ratio
-0.13
Price/Book
0.67
Profitability
Gross Margin
32.24%
Operating Margin
-2707.69%
Net Margin
-2981.25%
Return on Equity
-257.81%
EPS
$-17.05
Balance Sheet
Current Ratio
2.54
Quick Ratio
2.48
Other
Beta (Volatility)
1.02
Does PCSA Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Stable - The moat is dependent on successful clinical development and subsequent patent protection; currently stable but highly vulnerable.
Moat Sources
1 Identified
The durability of the moat hinges entirely on the successful clinical development and subsequent regulatory approval of its drug candidates. If trials fail, the IP loses significant value.
Moat Erosion Risks
- •Clinical trial failures or delays
- •Patent challenges or expiry
- •Emergence of superior competitive therapies from larger pharmas
PCSA Competitive Moat Analysis
Sign up to see competitive advantages
PCSA Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral - Speculative, driven by clinical milestones, with limited broader retail interest beyond biotech forums.
Institutional Sentiment
Negative - No analyst coverage or institutional ownership data suggests minimal institutional interest.
Insider Activity (Form 4)
CEO George K. Ng bought 1,843 shares ($5,473) on April 15, 2026. CFO Russell Skibsted bought 1,984 shares ($5,892) on April 15, 2026. Pres. R&D David Young bought 1,545 shares ($4,589) on April 15, 2026. CBO Patrick Lin bought 1,369 shares ($4,065) on April 15, 2026. CDO Sian Bigora bought 1,799 shares ($5,343) on April 15, 2026. All purchases at $2.97/share, indicating internal conviction.
Options Flow
Normal options activity; due to micro-cap status, options market is likely illiquid and not indicative of institutional positioning.
Earnings Intelligence
Next Earnings
Estimated early-June 2026 (for Q1 2026, typically within 45 days of quarter end)
Surprise Probability
Low - As a pre-revenue company, 'surprise' is usually tied to clinical updates or cash runway, not traditional EPS/revenue.
Historical Earnings Pattern
Typically volatile reactions to clinical news; earnings reports without substantial clinical updates tend to be non-events or slight downward pressure due to ongoing losses.
Key Metrics to Watch
Competitive Position
Top Competitor
N/A (no direct comparable specified, but broadly other clinical-stage oncology biotechs with similar trial phases, e.g., OncoSec Medical (ONCS) or similar micro-cap names)
Market Share Trend
Not applicable; pre-commercial.
Valuation vs Peers
Difficult to compare on traditional metrics (P/E, P/S) due to pre-revenue status. Valuation is entirely based on pipeline potential, which puts it at a highly speculative premium relative to its current financial state but a significant discount if any drug achieves success.
Competitive Advantages
- •Proprietary small molecule drug candidates (e.g., PCS-3117, NGC-Cap) for unmet needs in oncology
- •Experienced management team in drug development
- •Focus on specific, potentially less crowded oncology niches
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive PCSA Stock Higher?
Near-Term (0-6 months)
- •Interim Phase 2 NGC-Cap data in H1 2026 (expected within next ~2 months)
- •Potential partnership discussions following interim data
Medium-Term (6-18 months)
- •Full Phase 2 NGC-Cap data readout and End-of-Phase 2 meeting with FDA (late 2026/early 2027)
- •Initiation of Phase 3 trials for NGC-Cap (if successful Phase 2)
- •Advancement of other pipeline candidates (PCS-3117)
Long-Term (18+ months)
- •Regulatory approval and commercialization of NGC-Cap (2028-2030)
- •Expansion into additional indications or markets
- •Establishment as a niche oncology player
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for PCSA?
- ✓
Positive Phase 2 NGC-Cap interim results (efficacy, safety)
- ✓
Significant non-dilutive funding or partnership announcements
- ✓
Improved cash position and runway in future 10-Q/10-K filings
Bull Case Analysis
See what could go right with Premium
Competing with PCSA
See how Processa Pharmaceuticals Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Processa Pharmaceuticals Inc PCSA | $7.0M | 4.0 | -0.1 | — | -2981.3% | — | |
AbbVie Inc ABBV | $403.8B | 0.1 | 171.8 | — | — | — | Compare → |
Johnson & Johnson JNJ | — | 1.0 | — | — | — | — | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $150.6B | 0.2 | 19.4 | $62.6B | 12.4% | -1.6% | Compare → |
UnitedHealth Group Inc UNH | $276.2B | 0.3 | 22.9 | $113.7B | 2.7% | 1181.0% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Processa Pharmaceuticals Inc Makes Money
Processa Pharmaceuticals is a clinical-stage pharmaceutical company focused on developing small molecule drugs for cancer and other unmet medical needs. It does not currently generate revenue from product sales. Its business model involves conducting pre-clinical and clinical trials (Phases 1, 2, 3) to demonstrate the safety and efficacy of its proprietary drug candidates. If successful, the company aims to seek regulatory approvals (e.g., FDA) to commercialize these drugs itself or, more likely given its size, through licensing agreements or partnerships with larger pharmaceutical companies, which would provide milestone payments and royalties. The company relies heavily on equity financing and grants to fund its research and development activities.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Processa Pharmaceuticals Inc (PCSA)?
As of April 30, 2026, Processa Pharmaceuticals Inc has a DVR Score of 4.0 out of 10, placing it in the "Proceed with Caution" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Processa Pharmaceuticals Inc?
Processa Pharmaceuticals Inc's market capitalization is approximately $7.0M. The company operates in the Healthcare sector within the Biotechnology industry.
What ticker symbol does Processa Pharmaceuticals Inc use?
PCSA is the ticker symbol for Processa Pharmaceuticals Inc. The company trades on the NCM.
What is the risk level for PCSA stock?
Our analysis rates Processa Pharmaceuticals Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of PCSA?
Processa Pharmaceuticals Inc currently has a price-to-earnings (P/E) ratio of -0.1. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Is PCSA stock profitable?
Processa Pharmaceuticals Inc has a profit margin of -2981.3%. The company is currently unprofitable.
How often is the PCSA DVR analysis updated?
Our AI-powered analysis of Processa Pharmaceuticals Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 30, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for PCSA (Processa Pharmaceuticals Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.